Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 2Suspended 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Lymphoid 1

Conditions

Basal Cell Nevus Syndrome 3Carcinoma, Basal Cell 2Skin Neoplasms 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 194aldesleukin 145Interleukin-2 109fludarabine phosphate 107Temozolomide 83fludarabine 81Dacarbazine 81Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Magnetic Resonance Spectroscopy 48Carboplatin 48Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42Specimen Handling 42atezolizumab 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × gusacitinib × Dermatologic × Clear all
NCT04416516 2024-04-10

Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor

Ascend Biopharmaceuticals Ltd

Phase 2 Completed
21 enrolled
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT03208296 2023-02-06

Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)

Ascend Biopharmaceuticals Ltd

Phase 1/2 Suspended
24 enrolled
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT02550678 2018-06-06

ASN-002-001

Ascend Biopharmaceuticals Ltd

Phase 1/2 Completed
16 enrolled
Dermatologic

Basal Cell Nevus Syndrome, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡